Previously, he served as Blueprint Medicines’ Senior Vice President, Clinical Development from May 2020 to January 2021. Kate currently serves as chair of the board of directors at Fulcrum Therapeutics and is a member of the audit and compensation committees.īecker brings 20 years of industry and clinical experience in oncology and hematology, including achieving the approval of three tyrosine kinase inhibitors. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including portfolio strategy, corporate development, commercial strategy, international, technical operations, corporate affairs, and information systems. Over this time, she served as the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. Previously, she served as Chief Operating Officer from January 2019 to April 2022, and as Chief Business Officer from January 2016 to January 2019. Since April 2022, Kate has served as Chief Executive Officer of Blueprint Medicines. Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, commercial and strategic planning, and program management. in business management from Bentley University. She serves as a member of the board of directors for the Massachusetts Biotechnology Education Foundation, a nonprofit organization committed to supporting science and biotechnology education in Massachusetts through school programs, workforce training and lifelong learning. ![]() Prior to Cubist, Debbie served as the North American manager of talent acquisition and workforce planning at Holcim, Inc., in Waltham, MA. Prior to this role, she was the global senior director for talent management and organizational development at Cubist, where she was primarily responsible for building talent and leadership strength and depth while managing change on a global scale to create a cohesive and highly differentiated culture. Most recently, Debbie served as the interim head of human resources for Cubist Pharmaceuticals, Inc., where she was appointed to lead the post-merger human resource integration following the acquisition of Cubist by Merck. In addition, he received an MBA from Massachusetts Institute of Technology.ĭebbie is an accomplished human resources executive with a focus on providing strategic direction to companies on people matters, managing rapid growth and creating and maintaining high performance cultures. in Organic Chemistry from Harvard University. in Chemistry from Dartmouth College and a Ph.D. patents, and has authored or co-authored numerous peer-reviewed publications. Percy is an inventor or co-inventor on more than 28 U.S. Prior to his experience at BMS, he was Senior Research Scientist in Chemical and Physical Sciences at DuPont Pharmaceuticals, until it was acquired by BMS in 2001. From August 2001 to May 2019, Percy held roles of increasing responsibility in drug discovery, covering all therapeutic areas, drug platforms and stages of discovery at Bristol-Myers Squibb (BMS), including serving as Senior Vice President and Head of Discovery. ![]() He previously served as Global Head of Discovery Sciences at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he led more than 700 employees comprising several key research and discovery functions, and drove the synthetic discovery strategy in collaboration with partners across various therapeutic areas. Prior to joining Blueprint Medicines, he served as Chief Scientific Officer at FibroGen, Inc. ![]() Percy brings more than 20 years of global leadership in pharmaceutical companies and industry experience.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |